Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease

Allan B. Dietz, Eric J. Dozois, Joel G. Fletcher, Greg W. Butler, Darcie Radel, Amy L. Lightner, Maneesh Dave, Jessica Friton, Asha Nair, Emily T. Camilleri, Amel Dudakovic, Andre J. van Wijnen, William A. Faubion

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

In patients with Crohn's disease, perianal fistulas recur frequently, causing substantial morbidity. We performed a 12-patient, 6-month, phase 1 trial to determine whether autologous mesenchymal stem cells, applied in a bioabsorbable matrix, can heal the fistula. Fistula repair was not associated with any serious adverse events related to mesenchymal stem cells or plug placement. At 6 months, 10 of 12 patients (83%) had complete clinical healing and radiographic markers of response. We found placement of mesenchymal stem cell−coated matrix fistula plugs in 12 patients with chronic perianal fistulas to be safe and lead to clinical healing and radiographic response in 10 patients. ClinicalTrials.gov Identifier: NCT01915927.

Original languageEnglish (US)
Pages (from-to)59-62.e2
JournalGastroenterology
Volume153
Issue number1
DOIs
StatePublished - Jul 2017

Keywords

  • Cell Therapy
  • Clinical Trial
  • IBD
  • STOMP Trial

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease'. Together they form a unique fingerprint.

Cite this